세계의 클로닝 및 돌연변이 유발 시장

Global Cloning and Mutagenesis Market to Reach US$10.3 Billion by 2030

The global market for Cloning and Mutagenesis estimated at US$3.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Cloning Kits, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Mutagenesis Kits segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$906.5 Million While China is Forecast to Grow at 18.7% CAGR

The Cloning and Mutagenesis market in the U.S. is estimated at US$906.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Cloning and Mutagenesis Market - Key Trends & Drivers Summarized

What Is Driving the Surging Demand for Cloning and Mutagenesis?

Cloning and mutagenesis have become integral components in various fields such as biotechnology, pharmaceuticals, and agricultural sciences. The increasing demand for genetically modified organisms (GMOs) and biopharmaceuticals is a crucial driver of this market. In the healthcare sector, gene therapy advancements have propelled the demand for cloning technologies, particularly for regenerative medicine and precision oncology. Furthermore, the development of high-throughput mutagenesis techniques has significantly accelerated research in genetic engineering, enabling the creation of modified proteins with enhanced functionalities. The rising prevalence of chronic diseases such as cancer, diabetes, and genetic disorders has intensified research efforts in molecular biology, further fueling investments in cloning and mutagenesis tools. Additionally, the ability to manipulate genetic material for drug discovery and vaccine development is enhancing the market’s attractiveness, particularly with the ongoing exploration of mRNA technology. Pharmaceutical companies are leveraging these technologies to produce more effective therapeutic proteins, antibodies, and gene-editing solutions, which are seeing increased adoption worldwide.

How Is Technology Reshaping the Future of Cloning and Mutagenesis?

Advancements in CRISPR-Cas9 and other gene-editing technologies have revolutionized the cloning and mutagenesis landscape. The introduction of next-generation sequencing (NGS) has enabled precise genetic modifications, drastically reducing time and cost constraints traditionally associated with these techniques. With automation and AI-driven workflows, laboratories are now able to execute high-throughput mutagenesis experiments with greater efficiency, ensuring faster turnaround times for research and product development. Moreover, the convergence of synthetic biology with cloning and mutagenesis is facilitating the creation of novel biosynthetic pathways, thereby expanding the application scope of these technologies. The emergence of directed evolution approaches, where mutagenesis is used to artificially enhance protein functions, has gained traction in enzyme engineering and industrial biotechnology. Researchers are also focusing on improving site-directed mutagenesis techniques to enable more precise genetic alterations, minimizing off-target effects and increasing reliability in experimental outcomes.

What Are the Key Market Trends That Are Shaping the Competitive Landscape?

The market landscape for cloning and mutagenesis is increasingly competitive, with companies investing heavily in research and development to gain a technological edge. A significant trend driving market expansion is the rise of contract research organizations (CROs) that provide specialized cloning and mutagenesis services. This shift is particularly notable in pharmaceutical and biotech firms, which are outsourcing research to reduce costs and accelerate time-to-market for new drugs. Another emerging trend is the adoption of cloud-based bioinformatics platforms that allow researchers to design and analyze mutagenesis experiments remotely, facilitating collaboration and improving data accuracy. Additionally, the proliferation of open-access genetic databases is enabling scientists to leverage vast genetic information repositories for more informed cloning experiments. The increasing funding for synthetic biology and precision medicine is expected to spur further innovations, as stakeholders seek to develop more personalized therapeutic interventions.

What Are the Growth Drivers Fueling Market Expansion?

The growth in the cloning and mutagenesis market is driven by several factors, including rising investments in genomic research, increasing applications in drug discovery, and the expanding role of synthetic biology. The pharmaceutical industry’s reliance on mutagenesis for antibody development and vaccine research has intensified post-pandemic, leading to higher adoption rates of genetic engineering tools. Moreover, advancements in agriculture biotechnology, such as the creation of genetically modified crops resistant to pests and harsh environmental conditions, are propelling the demand for cloning technologies. The need for more efficient production of recombinant proteins and biofuels has also driven the adoption of advanced mutagenesis techniques in industrial biotechnology. Additionally, regulatory support and government funding for genome-editing projects are further boosting market expansion, making cloning and mutagenesis an essential pillar of future scientific innovations.

SCOPE OF STUDY:

The report analyzes the Cloning and Mutagenesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cloning Kits, Mutagenesis Kits, Other Product Types); Technology (Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology, Other Technologies); End-Use (Biopharmaceutical and Pharmaceutical Companies End-Use, CROs and CMOs End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

• Agilent Technologies, Inc.
• Assay Genie
• Bio-Rad Laboratories, Inc.
• Bolder BioTechnology, Inc.
• Creative Biogene
• Danaher Corporation
• Genes2Me
• Genewiz (Azenta Life Sciences)
• Genomax Technologies Pte Ltd
• GenScript
• Integrated DNA Technologies (IDT)
• Jena Bioscience GmbH
• Merck KGaA
• New England Biolabs
• OriGene Technologies
• Promega Corporation
• Takara Bio Inc.
• Thermo Fisher Scientific, Inc.
• TransGen Biotech Co., Ltd.
• Vazyme

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cloning and Mutagenesis - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Applications of Functional Genomics and Protein Engineering Propel Growth of Cloning and Mutagenesis Tools
  • Expanding Biopharmaceutical R&D Activity Drives Demand for High-Fidelity Gene Cloning and Mutagenesis Technologies
  • Advancements in Site-Directed Mutagenesis Enhance Efficiency of Precision Genetic Modifications
  • Growing Use of Recombinant DNA Technologies in Synthetic Biology Expands Adoption of Cloning Techniques
  • Increased Demand for Custom Gene Synthesis and Expression Cloning Generates Market Opportunities
  • Rapid Progress in CRISPR and Genome Editing Research Spurs Adoption of Mutagenesis Protocols
  • Integration of Automation and High-Throughput Screening Enhances Workflow Efficiency in Cloning and Mutagenesis Labs
  • Expansion of Academic and Research Institutions Globally Strengthens Demand for Gene Manipulation Kits
  • Rising Focus on Protein Structure-Function Studies Propels Market for Directed Evolution and Mutagenesis
  • Growing Biotech Startup Activity Accelerates Commercial Use of Cloning Vectors and Mutation Libraries
  • Increased Application of Mutagenesis in Vaccine Development Drives Market Growth
  • Adoption of Mutagenesis Techniques for Enzyme Optimization and Industrial Biocatalysts Expands Use Cases
  • Rising Investments in Agricultural Biotechnology Fuel Demand for Plant Gene Cloning and Trait Improvement
  • Growing Trend Toward Personalized Medicine Supports Custom Gene Editing and Cloning Solutions
  • Availability of Cloud-Based Bioinformatics Tools Enhances Adoption of Cloning and Mutagenesis Protocols
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cloning and Mutagenesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Cloning Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Cloning Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Mutagenesis Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Mutagenesis Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Topo PCR Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Topo PCR Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Site-directed Mutagenesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Site-directed Mutagenesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Blunt End Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Blunt End Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Seamless Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Seamless Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 24: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 25: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 30: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: USA 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 36: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Canada 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• JAPAN
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 42: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: Japan 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• CHINA
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 48: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 49: China 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• EUROPE
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• FRANCE
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 58: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: France 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• GERMANY
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Germany 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• ITALY
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Italy 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• UNITED KINGDOM
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 76: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: UK 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• ASIA-PACIFIC
  • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION